Survodutide, a dual GLP-1 and glucagon receptor agonist, produced around 19 percent weight loss in phase 2 trials
Its a strategy of saying, All right, if we pop our head over the barbed wire fence, is anybody going to take a shot? Novo launched the drug in the beginning of January and has seen strong demand in the U.S., where it is available on its cash-pay direct-to-consumer website
"To control blood glucose spikes, combine protein with carbohydrates, like rice with beans, or cottage cheese or yogurt with fruit," says Nasser
If you're wondering what realistic maintenance looks like in day-to-day life, this guide on how to maintain weight loss is a helpful next read
The clinical significance of anti-exenatide antibody formation is unknown at this time